Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
5 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Fresenius-controlled mAbxience signed a licensing, development, manufacturing, marketing deal with Sandoz for an emicizumab biosimilar candidate. mAbxience will develop and manufacture in GMP-certified plants in Spain, Argentina; Sandoz gets exclusive global marketing rights excluding Argentina, Uruguay, Paraguay. Proj
EQS-News: mAbxience / Key word(s): Agreement/Miscellaneous mAbxience and Sandoz Sign a Collaboration Agreement to Advance Biosimilar Access Worldwide 18.09.2026 / 12:35 CET/CEST The issuer is solely responsible for the content of this announcement. ═══════════════════════════════════════════════════════════════════════
mAbxience and Sandoz agreed to develop, manufacture and commercialize an emicizumab biosimilar. Sandoz holds exclusive global rights excluding Argentina, Uruguay and Paraguay.
Sandoz signed a licensing, development, manufacturing, commercialisation deal with mAbxience for a proposed emicizumab biosimilar. Agreement gives Sandoz exclusive global commercialisation rights, excluding Argentina, Uruguay, Paraguay; mAbxience will handle development, manufacturing. Targets Hemlibra reference market
Sandoz Group AG / Key word(s): Agreement Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing biosimilar medicines 18.09.2026 / 07:15 CET/CEST ══════════════════════════════════════════════════════════════════════════════════════════════════════ Media Release • Agreement for emicizum